BioSpace News Archive

HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced the company will be participating in the upcoming Morgan Stanley Global Healthcare Conference.

Meridian Bioscience, Inc., a provider of diagnostic testing solutions and life science raw materials, announced its wholly owned subsidiary, Magellan Diagnostics, Inc., expanded the Class I recall of its LeadCare® II Blood Lead Test Kits, LeadCare Plus® Blood Lead Test Kits, and LeadCare Ultra® Blood Lead Test Kits for the detection of lead in whole blood.

OncoQuest Pharmaceuticals Inc., (“OncoQuest”) a clinical-stage biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer, today announces the first patient enrolled in each of two investigator initiated clinical trials assessing the safety and efficacy of oregovomab in a previously treated recurrent ovarian cancer setting.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801),, and GenFleet Therapeutics (Shanghai) Inc. (“GenFleet”), today jointly announced that they have entered into an exclusive license agreement for the development and commercialization of GenFleet’s lead KRAS G12C candidate.

Cue Health Inc. (“Cue Health” or “Cue”), a health technology company, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its common stock.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA® (zanubrutinib) has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).

BioLife Solutions, Inc. announces that it has filed a registration statement on Form S-3 with the Securities and Exchange Commission to register approximately 10.7 million shares of restricted common stock held by stockholders of previously acquired companies Global Cooling, Inc., SciSafe Holdings, Inc. and Sexton Biotechnologies, Inc., as well as certain shares held by Casdin Capital.

THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, announced the appointment of Stuart F. Simpson as its president and chief executive officer.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced efforts in recognition of Sepis Awareness Month to educate on the importance of rapid diagnostic technologies at a time when sepsis is the most common complication observed in severe cases of COVID-19.1,2

For two years, Critical Path Institute, the National Organization for Rare Disorders and the U.S. Food and Drug Administration have joined with others throughout the rare disease community to create a novel, best-in-class platform to accelerate rare disease treatment innovation.